Abstract
Bloodstream infections (BSI) represent a significant global health challenge, and traditional diagnostic methods are suboptimal for timely guiding targeted antibiotic therapy. We introduce MultiSeq-AMR, an ultra-fast amplicon sequencing workflow to identify bacterial and fungal species, and a comprehensive set of antimicrobial resistance (AMR) genes (n = 91) for BSI diagnosis. We initially benchmarked MultiSeq-AMR using DNA from 21 bacterial and fungal isolates and accurately identified 100% species and 99.4% AMR genes. Further validation with 33 BACT/ALERT positive samples from suspected BSI cases revealed 100% accuracy for pathogen identification with mono-bacterial samples, with 97.4% categorical agreement (CA) for AMR gene prediction. To accelerate diagnosis, 6-hour culture-enrichment combined with MultiSeq-AMR identified 11/13 species with 96% CA for AMR gene identification. MultiSeq-AMR holds promise for improving patient outcomes as species/AMR genes could be identified in under 5 hours of BACT/ALERT positivity, and potentially <11 hours of sample collection.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Royal Society Research Grant (RGS\R1\211163) and University of Glasgow Lord Kelvin Adam Smith (LKAS) Ph.D. studentship provided funding for this study.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by UK National Health Services (NHS) Greater Glasgow and Clyde (R&I reference: GN19ID331), and the University of Glasgow College of Medical, Veterinary & Life Sciences Ethics Committee (Project No: 200210015). Blood culture samples from all the individuals suspected of having BSI were taken as a part of routine clinical care and no personal information from the patients or from the healthy human volunteers was collected and used in this study.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
6
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos